Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Medtronic
Farmers Insurance
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Cerilliant
Covington
Federal Trade Commission

Generated: October 20, 2017

DrugPatentWatch Database Preview

ZERIT XR Drug Profile

« Back to Dashboard

Which patents cover Zerit Xr, and what generic Zerit Xr alternatives are available?

Zerit Xr is a drug marketed by Bristol Myers Squibb and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in ZERIT XR is stavudine. There are fourteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the stavudine profile page.

Summary for Tradename: ZERIT XR

US Patents:1
Applicants:1
NDAs:1
Bulk Api Vendors: see list77
Clinical Trials: see list11
Patent Applications: see list5,310
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ZERIT XR at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
ZERIT XR
stavudine
CAPSULE, EXTENDED RELEASE;ORAL021453-001Dec 31, 2002DISCNNoNo► Subscribe► SubscribeY► Subscribe
Bristol Myers Squibb
ZERIT XR
stavudine
CAPSULE, EXTENDED RELEASE;ORAL021453-004Dec 31, 2002DISCNNoNo► Subscribe► SubscribeY► Subscribe
Bristol Myers Squibb
ZERIT XR
stavudine
CAPSULE, EXTENDED RELEASE;ORAL021453-002Dec 31, 2002DISCNNoNo► Subscribe► SubscribeY► Subscribe
Bristol Myers Squibb
ZERIT XR
stavudine
CAPSULE, EXTENDED RELEASE;ORAL021453-003Dec 31, 2002DISCNNoNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZERIT XR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb
ZERIT XR
stavudine
CAPSULE, EXTENDED RELEASE;ORAL021453-001Dec 31, 2002► Subscribe► Subscribe
Bristol Myers Squibb
ZERIT XR
stavudine
CAPSULE, EXTENDED RELEASE;ORAL021453-003Dec 31, 2002► Subscribe► Subscribe
Bristol Myers Squibb
ZERIT XR
stavudine
CAPSULE, EXTENDED RELEASE;ORAL021453-004Dec 31, 2002► Subscribe► Subscribe
Bristol Myers Squibb
ZERIT XR
stavudine
CAPSULE, EXTENDED RELEASE;ORAL021453-002Dec 31, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Cantor Fitzgerald
Johnson and Johnson
Moodys
McKinsey
Julphar
Harvard Business School
Boehringer Ingelheim
UBS
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot